Published : Nov-2017
No. of Pages : 449
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Genetic Testing Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Genetic Testing Market, United States 7
3.1 Genetic Testing Market, United States, Revenue ($m), 2010-2017 7
3.2 Genetic Testing Market, United States, Revenue ($m), 2017-2024 9
3.3 Genetic Testing Market, United States, Distribution Share by Revenue ($m), 2017 11
3.4 Genetic Testing Market, United States, Company Share by Revenue ($m), 2017 12
4 Overview of Key Companies in United States, Genetic Testing Market 14
4.1 F. Hoffmann-La Roche Ltd 14
4.2 Abbott Laboratories 14
4.3 Luminex Corp 14
4.4 PerkinElmer Inc 15
4.5 Myriad Genetics Inc 15
4.6 Hologic Inc 15
4.7 Qiagen NV 16
5 Genetic Testing Market Pipeline Products 17
6 Financial Deals Landscape 19
6.1 Acquisition 19
6.2 Debt Offerings 29
6.3 Equity Offerings 50
6.4 Merger 74
6.5 Partnerships 76
6.6 Venture Financing 97
7 Recent Developments 115
7.1 Corporate Communications 115
7.2 Financial Announcements 168
7.3 Government and Public Interest 308
7.4 Legal And Regulatory 311
7.5 Other Significant Developments 318
7.6 Product News 347
7.7 Strategy And Business Planning 423
8 Appendix 429
8.1 Research Methodology 430
8.2 GlobalData Consulting 434
8.3 Contact Us 435
8.4 Disclaimer 435
1.1 List of Tables
Table 1: Genetic Testing Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 22
Table 2: Genetic Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 24
Table 3: Genetic Testing Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017 25
Table 4: Genetic Testing Market, United States, Company Share by Revenue ($m), USD Constant, 2017 27
Table 5: Genetic Testing Market Pipeline Products 31
Table 6: Invitae to Acquire Good Start Genetics 33
Table 7: Invitae to Acquire CombiMatrix for USD33 Million 35
Table 8: NantOmics Acquires Genos Research 37
Table 9: Omicia Acquires Spiral Genetics 38
Table 10: Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 39
Table 11: Takara Bio Acquires Rubicon Genomics for USD75 Million 41
Table 12: DNA Diagnostics Center Acquires Identigene from Sorenson Genomics 42
Table 13: Hologic Raises USD350 Million in Private Placement of 4.375% Notes Due 2025 43
Table 14: LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024 44
Table 15: LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027 46
Table 16: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 48
Table 17: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 50
Table 18: Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 52
Table 19: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 54
Table 20: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 56
Table 21: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 58
Table 22: Interleukin Genetics Raises USD1 million in Issue of Subordinated Convertible Promissory Notes 60
Table 23: Transgenomic Raises USD1.2 Million in Private Placement 61
Table 24: Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 62
Table 25: CareDx Raises USD20 Million in Public Offering of Shares 64
Table 26: NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 66
Table 27: Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 67
Table 28: CareDx Files Registration Statement to Raise Funds through Public Offering of Shares 69
Table 29: Biocept Plans to Raise Funds through Private Placement of Shares 70
Table 30: Invitae to Raise Funds through Public Offering of Shares 71
Table 31: Invitae to Raise Funds through Public Offering of Shares 72
Table 32: Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 73
Table 33: Fluidigm Raises USD30 Million in Public Offering of Shares 75
Table 34: Trovagene to Raise USD7 Million in Private Placement of Shares and Warrants 76
Table 35: Interpace Diagnostics Raises USD13.7 Million in Public Offering of Share and Warrants 77
Table 36: NanoString Technologies Raises USD57.8 Million in Public Offering of Shares 79
Table 37: CareDx Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 80
Table 38: HTG Molecular Diagnostics to Raise up to USD20 Million in Public Offering of Shares 81
Table 39: Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 82
Table 40: Biocept Prices Private Placement of Shares and Warrants for USD9.3 Million 83
Table 41: Interpace Diagnostics Raises USD3.9 Million in Public Offering of Shares 84
Table 42: Invitae Prices Public Offering of Shares for USD44 Million 86
Table 43: Protea Biosciences Group Raises USD0.6 Million in Private Placement 87
Table 44: Signal Genetics Merges with miRagen Therapeutics 88
Table 45: NuGEN Technologies Enters into Agreement with Cambridge Epigenetix 90
Table 46: Taconic Biosciences Enters into Agreement with Cergentis 91
Table 47: Agena Bioscience Enters into Co-Marketing Agreement with HeartGenetics 92
Table 48: Novogene Enters into Agreement with Pacific Biosciences 93
Table 49: AstraZeneca Enters into Partnership with DNAnexus 94
Table 50: Rady Children's Hospital and Alexion Pharma Enter into Agreement 95
Table 51: University of Rochester School of Medicine and Dentistry and Admera Health Enter into Partnership 96
Table 52: Hamilton Robotics Partners with Illumina 97
Table 53: Lucigen Enters into Distribution Agreement with Illumina 98
Table 54: Fabric Genomics and TOMA Biosciences Enter into Partnership 99
Table 55: Kailos Genetics Enters into Co-Marketing Agreement with Illumina 100
Table 56: ThermaGenix Enters Licensing Agreement with Brandeis University 101
Table 57: OncoSec Medical Enters into Agreement with Inhibrx 102
Table 58: Analytik Jena Enters into Co-Development Agreement with Illumina 103
Table 59: Asuragen Enters into Agreement with Thermo Fisher Scientific 104
Table 60: RPRD Diagnostics Enters into Partnership with Children's Minnesota 105
Table 61: Bio-Reference Labs Terminates its Distribution Agreement with Natera for NIPD Test 106
Table 62: Invitae Enters into Clinical Research Agreement with TME Research 107
Table 63: Regeneron Genetics Center Enters into Research Agreement with Children's National Health System 108
Table 64: OpGen Enters into Research Agreement with Merck 109
Table 65: NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 110
Table 66: 23andMe Raises USD250 Million in Venture Financing 111
Table 67: WuXi NextCODE Raises Additional USD165 Million in Series B Financing 113
Table 68: InVitae Raises USD16 Million in Venture Financing 114
Table 69: Kailos Genetics Raises Funds through Venture Financing 115
Table 70: Genome Profiling Raises USD0.9 Million in Venture Financing 116
Table 71: Personalis Raises USD12.2 Million in Venture Financing 117
Table 72: iNanoBio to Raise USD4 Million in Venture Financing 118
Table 73: WuXi NextCODE Raises USD75 Million in Series B Financing 119
Table 74: AltheaDx Raises USD27 Million in Series D Financing 120
Table 75: Geneticure Raises USD0.2 Million in Venture Financing 121
Table 76: Muse Biotechnology Raises USD23 Million in Series B Venture Financing 122
Table 77: Exonics Therapeutics Raises USD5 Million in Seed Financing 123
Table 78: Genomind Raises USD11 Million in Venture Financing 124
Table 79: Bio-Nems Raises USD0.2 Million in Venture Financing 125
Table 80: Kailos Genetics to Raise USD2 Million in Venture Financing 126
Table 81: Genos Research Raises USD6 Million in Seed Financing 127
Table 82: Inform Genomics to Raise USD1.4 Million in Venture Financing 128
Table 83: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 446
1.2 List of Figures
Figure 1: Genetic Testing Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 21
Figure 2: Genetic Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 23
Figure 3: Genetic Testing Market, United States, Company Share (%) 2017 26
